Comments
Drug major Cipla today said it has received approval from the World Health Organisation (WHO) for Q-TIB, a combination drug indicated to help prevent tuberculosis infection in people living with HIV.
Q-TIB is a novel fixed dose combination in a single tablet and it is for the first time that such a combination has been made available in the world.
The company will market the product globally, Cipla said in a statement.
Q-TIB will help prevent tuberculosis infection in people living with HIV as they face a challenged immune system and are prone to infections, which constitute the major source of premature deaths among them.
According to WHO’s Global TB Report, 2016, about one million people died of AIDS-related illness. Most of them succumbed to infections, and among them, 4 lakh died of tuberculosis.
Cipla shares were trading 1.31 per cent down at Rs 600.55 apiece on the BSE today.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.